Jubilant Life Sciences Ltd on Monday announced that its subsidiary, Jubilant Generics, has launched remdesivir for injection, under the brand name `JUBI-R`, in the Indian market at a price of Rs 4,700 per vial of 100 mg.

The company said it will make the drug available to over 1,000 hospitals providing Covid-19 treatment in India through its distribution network.

In May this year, Jubilant entered into a non-exclusive Licensing Agreement with Gilead Sciences that granted it the right to register, manufacture and sell Gilead`s investigational drug remdesivir in 127 countries including India.

Read more at Zee Business